Statin use and the risk of Alzheimer’s disease: The MIRAGE Study

[1]  S. Feasson,et al.  MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20536 high-risk individuals : a randomised placebo-controlled trial. , 2008 .

[2]  Lewis H Kuller,et al.  Statin use and the risk of incident dementia: the Cardiovascular Health Study. , 2005, Archives of neurology.

[3]  Patrick Browne,et al.  Atorvastatin for the treatment of mild to moderate Alzheimer disease: preliminary results. , 2005, Archives of neurology.

[4]  M. Etminan,et al.  Season of birth and risk of brain tumors in adults , 2004, Neurology.

[5]  D. Sparks,et al.  Do statins reduce risk of incident dementia and Alzheimer disease? The Cache County Study. , 2005, Archives of general psychiatry.

[6]  E. B. Larson,et al.  Statin therapy and risk of dementia in the elderly , 2004, Neurology.

[7]  G. McGwin,et al.  Association between Statin Use and Alzheimer’s Disease , 2004, Neuroepidemiology.

[8]  R. Green,et al.  Depression as a risk factor for Alzheimer disease: the MIRAGE Study. , 2003, Archives of neurology.

[9]  A. Salam.  Expanding indications of statins; implications of the Heart Protection Study , 2003, Expert opinion on investigational drugs.

[10]  P. Macfarlane,et al.  Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial , 2002, The Lancet.

[11]  AndrewJ. S. Coats.  MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial , 2002, The Lancet.

[12]  V. Hirth,et al.  The impact of the use of statins on the prevalence of dementia and the progression of cognitive impairment. , 2002, The journals of gerontology. Series A, Biological sciences and medical sciences.

[13]  D. Paris,et al.  Statins inhibit Aβ-neurotoxicity in vitro and Aβ-induced vasoconstriction and inflammation in rat aortae , 2002 .

[14]  Kenneth Rockwood,et al.  Use of lipid-lowering agents, indication bias, and the risk of dementia in community-dwelling elderly people. , 2002, Archives of neurology.

[15]  R. Green,et al.  Risk of dementia among white and African American relatives of patients with Alzheimer disease. , 2002, JAMA.

[16]  S. Yusuf.  MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Commentary , 2002 .

[17]  A. Koudinov,et al.  The levels of soluble amyloid beta in different high density lipoprotein subfractions distinguish Alzheimer's and normal aging cerebrospinal fluid: implication for brain cholesterol pathology? , 2001, Neuroscience Letters.

[18]  L. Launer,et al.  Cholesterol and neuropathologic markers of AD: A population-based autopsy study , 2001 .

[19]  L. Launer,et al.  Cholesterol and neuropathologic markers of AD , 2001, Neurology.

[20]  Paul M. Ridker,et al.  Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. , 2001, The New England journal of medicine.

[21]  S. Kasner,et al.  Use of statins in CNS disorders , 2001, Journal of the Neurological Sciences.

[22]  J. Buxbaum,et al.  Treatment with controlled-release lovastatin decreases serum concentrations of human beta-amyloid (A beta) peptide. , 2001, The international journal of neuropsychopharmacology.

[23]  R. Green,et al.  Reliability of Information Collected by Proxy in Family Studies of Alzheimer’s Disease , 2001, Neuroepidemiology.

[24]  C. Bergmann,et al.  Simvastatin strongly reduces levels of Alzheimer's disease β-amyloid peptides Aβ42 and Aβ40 in vitro and in vivo , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[25]  C. Schweiger.  [Statins and the risk of dementia]. , 2001, Italian heart journal. Supplement : official journal of the Italian Federation of Cardiology.

[26]  B. Davis,et al.  Reduction of Stroke Events With Pravastatin: The Prospective Pravastatin Pooling (PPP) Project , 2001, Circulation.

[27]  Y. Zhi.  Apolipoprotein E Alleles, Dyslipidemia,and Coronary Heart Disease , 2001 .

[28]  J. Buxbaum,et al.  Cholesterol depletion with physiological concentrations of a statin decreases the formation of the Alzheimer amyloid Abeta peptide. , 2001, Journal of Alzheimer's disease : JAD.

[29]  H Jick,et al.  Statins and the risk of dementia , 2000, The Lancet.

[30]  C. Mulrow,et al.  Use of lipid lowering drugs for primary prevention of coronary heart disease: meta-analysis of randomised trials , 2000, BMJ : British Medical Journal.

[31]  G. Celesia,et al.  Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. , 2000, Archives of neurology.

[32]  Rong Wang,et al.  Hypercholesterolemia Accelerates the Alzheimer's Amyloid Pathology in a Transgenic Mouse Model , 2000, Neurobiology of Disease.

[33]  C. DeCarli,et al.  Head injury and the risk of AD in the MIRAGE study , 2000, Neurology.

[34]  W. März,et al.  HMG-CoA Reductase Inhibition: Anti-Inflammatory Effects beyond Lipid Lowering? , 2000, Herz.

[35]  K. Hall,et al.  Serum cholesterol, APOE genotype, and the risk of Alzheimer’s disease: A population-based study of African Americans , 2000, Neurology.

[36]  J. Larosa,et al.  Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. , 1999, JAMA.

[37]  R. Laaksonen,et al.  Low-density lipoprotein-independent effects of statins. , 1999, Current opinion in lipidology.

[38]  R. Mayeux,et al.  APOE genotype, plasma lipids, lipoproteins, and AD in community elderly , 1999, Neurology.

[39]  R. Mayeux,et al.  Low-density lipoprotein cholesterol and the risk of dementia with stroke. , 1999, JAMA.

[40]  B. Strooper,et al.  Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[41]  T. Dyrks,et al.  Cationic lipids (lipofectamine) and disturbance of cellular cholesterol and sphingomyelin distribution modulates gamma-secretase activity within amyloid precursor protein in vitro. , 1998, Prostaglandins & other lipid mediators.

[42]  Irma-Leena Notkola,et al.  Serum Total Cholesterol, Apolipoprotein E {FC12}e4 Allele, and Alzheimer’s Disease , 1998, Neuroepidemiology.

[43]  R. Brookmeyer,et al.  A prospective study of estrogen replacement therapy and the risk of developing Alzheimer''s disease , 1997 .

[44]  J. Haines,et al.  Effects of Age, Sex, and Ethnicity on the Association Between Apolipoprotein E Genotype and Alzheimer Disease: A Meta-analysis , 1997 .

[45]  W. Markesbery.  Neuropathological Criteria for the Diagnosis of Alzheimer’s Disease , 1997, Neurobiology of Aging.

[46]  R. Brookmeyer,et al.  A prospective study of estrogen replacement therapy and the risk of developing Alzheimer's disease , 1997, Neurology.

[47]  P Woodbury,et al.  A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. , 1997, The New England journal of medicine.

[48]  H. Krumholz,et al.  When to start cholesterol-lowering therapy in patients with coronary heart disease. A statement for healthcare professionals from the American Heart Association Task Force on Risk Reduction. , 1997, Circulation.

[49]  P. Ianna,et al.  Secretory processing of amyloid precursor protein is inhibited by increase in cellular cholesterol content. , 1997, The Biochemical journal.

[50]  D. Sparks,et al.  Activation of microglia in the brains of humans with heart disease and hypercholesterolemic rabbits , 1996, Journal of Molecular Medicine.

[51]  A. Hofman,et al.  Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer's disease in the Rotterdam Study , 1997, The Lancet.

[52]  C. Duijn,et al.  749 Evidence for major gene inheritance of Alzheimer disease in families of patients with and without APOE ε4. VS Rao , 1996, Neurobiology of Aging.

[53]  Yaakov Stern,et al.  Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease , 1996, The Lancet.

[54]  Patrick L. McGeer,et al.  Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease , 1996, Neurology.

[55]  D. Sparks,et al.  Intraneuronal β-amyloid immunoreactivity in the CNS , 1996, Neurobiology of Aging.

[56]  J. Growdon,et al.  Risk of dementia among relatives of Alzheimer's disease patients in the MIRAGE study , 1996, Neurology.

[57]  W. Klein,et al.  Cholesterol Modulates -Secretase Cleavage of Amyloid Precursor Protein (*) , 1996, The Journal of Biological Chemistry.

[58]  C. Duijn,et al.  Evidence for major gene inheritance of Alzheimer disease in families of patients with and without APOE ε4 , 1996 .

[59]  J. Haines,et al.  Evidence for major gene inheritance of Alzheimer disease in families of patients with and without apolipoprotein E epsilon 4. , 1996, American journal of human genetics.

[60]  W. Klein,et al.  Cholesterol modulates alpha-secretase cleavage of amyloid precursor protein. , 1996, The Journal of biological chemistry.

[61]  T. Scott,et al.  Severe cardiovascular disease and Alzheimer's disease: Senile plaque formation in cortical areas , 1996, Clinical anatomy.

[62]  D. Sparks,et al.  Increased incidence of neurofibrillary tangles (NFT) in non-demented individuals with hypertension , 1995, Journal of the Neurological Sciences.

[63]  E M Wijsman,et al.  Interactions of apolipoprotein E genotype, total cholesterol level, age, and sex in prediction of Alzheimer's disease , 1995, Neurology.

[64]  D. R. Gross,et al.  Increased density of cortical apolipoprotein E immunoreactive neurons in rabbit brain after dietary administration of cholesterol , 1995, Neuroscience Letters.

[65]  J. Stengård,et al.  Apolipoprotein E polymorphism predicts death from coronary heart disease in a longitudinal study of elderly Finnish men. , 1995, Circulation.

[66]  P A Wolf,et al.  Apolipoprotein E alleles, dyslipidemia, and coronary heart disease. The Framingham Offspring Study. , 1994, JAMA.

[67]  D. Arveiler,et al.  Impact of apolipoprotein E polymorphism on lipoproteins and risk of myocardial infarction. The ECTIM Study. , 1994, Arteriosclerosis and thrombosis : a journal of vascular biology.

[68]  J. Growdon,et al.  Interrater agreement for diagnosis of Alzheimer's disease , 1994, Neurology.

[69]  J. Breitner,et al.  Detection of dementia in the elderly using telephone screening of cognitive status , 1993 .

[70]  D. Sparks,et al.  Temporal Sequence of Plaque Formation in the Cerebral Cortex of Non-Demented Individuals , 1993, Journal of neuropathology and experimental neurology.

[71]  L. Kuller,et al.  Relation of apolipoprotein E phenotype to myocardial infarction and mortality from coronary artery disease. , 1993, The American journal of cardiology.

[72]  R. Katzman.,et al.  Education and the prevalence of dementia and Alzheimer's disease , 1993, Neurology.

[73]  A. Burns.  Clinical diagnosis of Alzheimer's disease , 1991 .

[74]  P. Allhoff,et al.  The Framingham Offspring Study , 1991 .

[75]  D. Sparks,et al.  Cortical senile plaques in coronary artery disease, aging and Alzheimer's disease , 1990, Neurobiology of Aging.

[76]  U. Beisiegel,et al.  The LDL–receptor–related protein, LRP, is an apolipoprotein E-binding protein , 1989, Nature.

[77]  M. Nieminen,et al.  Apoprotein E Polymorphism and Coronary Artery Disease: Increased Prevalence of Apolipoprotein E‐4 in Angiographically Verified Coronary Patients , 1989, Arteriosclerosis.

[78]  R. Mahley,et al.  Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. , 1988, Science.

[79]  C. Filley.  Diagnosis of Alzheimer's disease. , 1988, Colorado medicine.

[80]  Marshal F. Folstein,et al.  The telephone interview for cognitive status , 1988 .

[81]  C. Sing,et al.  Apolipoprotein E polymorphism and atherosclerosis. , 1988, Arteriosclerosis.

[82]  G. Assmann,et al.  Association of apolipoprotein E polymorphism, low-density lipoprotein cholesterol, and coronary artery disease. , 1986, Clinical chemistry.

[83]  Z. Khachaturian.  Diagnosis of Alzheimer's disease. , 1985, Archives of neurology.

[84]  C. Sing,et al.  Role of the apolipoprotein E polymorphism in determining normal plasma lipid and lipoprotein variation. , 1985, American journal of human genetics.

[85]  Vijaya L. Melnick,et al.  Alzheimer’s Dementia , 1985, Contemporary Issues in Biomedicine, Ethics, and Society.

[86]  M. Folstein,et al.  Clinical diagnosis of Alzheimer's disease , 1984, Neurology.

[87]  F. W. Robertson,et al.  Polymorphism at the Apoprotein‐E locus in relation to risk of coronary disease , 1984, Clinical genetics.

[88]  G. Assmann,et al.  Apolipoprotein E Polymorphism and Coronary Artery Disease , 1983, Arteriosclerosis.

[89]  G. Utermann,et al.  Polymorphism of apolipoprotein E and occurrence of dysbetalipoproteinaemia in man , 1977, Nature.